Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 520-529

  Zhang, Xiaoping ^a   Jordan, Paul ^b   Cristea, Laura ^c   Salgo, Miklos ^a   Farha, Rana ^a   Kolis, Stanley ^a   Lee, Lois S ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

electrocardiography; moxifloxacin; ritonavir; Saquinavir; thorough QT QTc study

Indexed keywords

MOXIFLOXACIN; PLACEBO; RITONAVIR PLUS SAQUINAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NEUROLOGIC DISEASE; NORMAL HUMAN; PRESYNCOPE; QT INTERVAL; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LEAST-SQUARES ANALYSIS; LONG QT SYNDROME; MALE; MIDDLE AGED; QUINOLINES; RITONAVIR; SAQUINAVIR; TORSADES DE POINTES; YOUNG ADULT;

EID: 84859089058     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011400071     Document Type: Article

References (15)

1. Invirase (saquinavir meyslate) capsules [package insert]. Nutley, NJ: Roche Laboratories; 2007. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/020628s033,021785s010lbl.pdf. Accessed November 13, 2010.
2. Anson B, Weaver J, Ackerman M, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682-686. (Pubitemid 40260891)
3. Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA. Ritonavir 100 mgdoes not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther. 2008;83:153-159.
4. International Conference onHarmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed Register. 2005;70:61134-61135.
5. Lee LS, Backholer Z, Zandt H, Kolis S, Salgo M, Zhang X. A randomized, double-blind, positive-controlled, 14-day multiple ascending dose study to investigate the safety, tolerability, and pharmacokinetics of saquinavir boosted with ritonavir in healthy subjects. Clin Pharmacol Ther. 2009;85(suppl):S90. Abstract PIII-71.
6. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Version 3. October 2006. http:// ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm#ctc-30. Accessed August 9, 2010.
7. Bazett H. An analysis of the time relationship to the electrocardiogram. Heart. 1920;7:353-367.
8. Fridericia L. Die systolen dauer imelektrokardiogramm bei normalen menschen und bei herzkranke. Acta Med Scand. 1920;53:469-486.
9. Zhang X, Silkey M, Schumacher M, Wang L, Raval H, Caulfield JP. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. J Clin Pharmacol. 2009;49:534-539.
10. Shah RR. Drug-induced QTdispersion: does it predict the risk of torsade de pointes? J Electrocardiol. 2005;38(1):10-18. (Pubitemid 40127171)
11. Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother. 2004;54:785-790. (Pubitemid 39386732)
12. Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J. 2005;24:874-879. (Pubitemid 41475921)
13. Boffito M, Dickinson L, Hill A, et al. Pharmacokinetics ofonce-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antivir Ther. 2004;9:423-429. (Pubitemid 38878758)
14. Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83:867-872. (Pubitemid 351704917)
15. Kurowski M, Sternfeld T, Sawyer A, Hill A, Möcklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 2003;4:94-100. (Pubitemid 36582291)